Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomised, open-label trial to assess the safety and efficacy of switching to tenofovir-emtricitabine [emtricitabine/tenofovir disoproxil fumarate] or abacavir-lamivudine [lamivudine/abacavir]: The STEAL Study.

Next Previous
X
Search
Trial Profile

A randomised, open-label trial to assess the safety and efficacy of switching to tenofovir-emtricitabine [emtricitabine/tenofovir disoproxil fumarate] or abacavir-lamivudine [lamivudine/abacavir]: The STEAL Study.

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 03 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Emtricitabine/tenofovir disoproxil fumarate (Primary) ; Lamivudine/abacavir (Primary) ; HIV protease inhibitors; Non-nucleoside reverse transcriptase inhibitors
  • Indications HIV infections; HIV-1 infections
  • Focus Pharmacodynamics; Therapeutic Use
  • Acronyms STEAL

    • Most Recent Events

    • 30 Aug 2011 Additional trial centre, investigator identified as reported by ClinicalTrials.gov.
    • 08 Jul 2011 New source added and integrated (Australian New Zealand Clinical Trials Registry, ACTRN012605000505606).
    • 08 Jul 2011 Additional lead trial center (University of New South Wales) added as reported by Australian New Zealand Clinical Trials Registry.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top